News

UMMS Researchers Make Progress in ALS Research

It has already been a year since the ALS Ice Bucket Challenge took the internet by storm, causing countless American households, celebrities and public figures to show support for ongoing efforts to find a cure for amyotrophic lateral sclerosis. In the wake of the viral campaign, a team of scientists…

Neuralstem Wins Patent Infringment Case on Stem Cell Technology

Biopharmaceutical company, Neuralstem, Inc. has just announced the US District Court in Maryland has decided to dismiss StemCell, Inc.’s previously filed patent infringement case with prejudice in StemCells, Inc. v. Neuralstem, Inc. in favor of Neuralstem, on July 22, 2015. Neuralstem is most known for its proprietary stem cell technology. It has…

Project ALS Reports All Donations From 2014 Ice Bucket Challenge Have Been Spent On Research

Social media sensation The Ice Bucket Challenge (an event that raised awareness for ALS) is celebrating its one-year anniversary, with the Project A.L.S. reporting it has now spent 100 percent of the donations raised during the 6-week challenge period on several research projects that have already revealed promising results. Amyotrophic lateral sclerosis (ALS) is a fatal and progressive…

Differences Among ALS Patients Might Be The Key to Novel Therapies

Amyotrophic lateral sclerosis (ALS) is a disease that involves the death of neurons that activate voluntary muscles. These muscles are called skeletal striated muscles and are responsible for our ability to walk, talk and even breathe. The disease, also known as Lou Gehrig’s or Charcot disease, is therefore characterized by stiff muscles, muscle twitching and…

Aquinnah Pharmaceuticals Receives $500,000 In Grants From ALS Association

Aquinnah Pharmaceuticals recently announced that it received two grants totalling $500,000 from the ALS Association to support research projects to find a cure and possible treatments for amyotrophic lateral sclerosis (ALS) patients. Aquinnah will utilize the grants to further the advance of its lead compounds targeting TDP-43 pathophysiology, which is found in almost 90…